Compared to Estimates, Apellis Pharmaceuticals (APLS) Q2 Earnings: A Look at Key Metrics

Core Insights - Apellis Pharmaceuticals, Inc. reported a revenue of $199.69 million for the quarter ended June 2024, marking a significant increase of 110.3% year-over-year [1] - The earnings per share (EPS) was -$0.28, an improvement from -$1.02 in the same quarter last year [1] - The revenue exceeded the Zacks Consensus Estimate of $189.47 million by 5.39%, while the EPS also surpassed the consensus estimate of -$0.33 by 15.15% [1] Revenue Breakdown - Product revenue, net was reported at $179.14 million, slightly below the nine-analyst average estimate of $182.18 million [3] - Licensing and other revenue reached $20.55 million, significantly higher than the average estimate of $7.63 million based on nine analysts [4] - Product revenue from EMPAVELI was $24.50 million, compared to the average estimate of $26.48 million from five analysts [5] - Product revenue from SYFOVRE was $154.60 million, which also fell short of the five-analyst average estimate of $157.98 million [6] Stock Performance - Over the past month, shares of Apellis Pharmaceuticals have returned +11.8%, outperforming the Zacks S&P 500 composite's +1.1% change [6] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [6]